Competition positioning Position Lumvoa as a direct competitor to Amgen's Tepezza in thyroid eye disease, highlighting first-to-market potential in commercial TED therapy and leveraging Viridian’s planned best-in-class subcutaneous option to differentiate from IV therapies.

Commercial readiness Leverage the FDA approval and US launch of Lumvoa to engage payers and clinics with established TED treatment pathways, emphasizing access programs and patient support via ViridianCares to accelerate payer coverage discussions.

Patient access Promote ViridianCares and coverage assistance to reduce the financial burden on patients, creating strong stakeholder engagement with patient advocacy groups and specialty pharmacies to drive adoption upon launch.

Manufacturing momentum Capitalize on the long-term WuXi Biologics manufacturing agreement to assure supply chain reliability for Lumvoa launch campaigns, enabling targeted outreach to contract manufacturers and specialty distributors.

Broader portfolio Highlight the expanding FcRn inhibitor pipeline (VRDN-006 and VRDN-008) as opportunities for cross-sell with TED physicians and autoimmune disease specialists, offering a broader disease area strategy for academic and pharmaceutical partners.